Similar articles

• Permanent intrinsic B cell immunodeficiency caused by phenytoin hypersensitivity.

  Guerra IC, Fawcett WA 4th, Redmon AH, Lawrence EC, Rosenblatt HM, Shearer WT. Guerra IC, et al. J Allergy Clin Immunol. 1986 Apr;77(4):603-7. doi: 10.1016/0091-6749(86)90353-2. J Allergy Clin Immunol. 1986. PMID: 3082959
• Response to transfer factor to immunodeficiency in handicaps treated with phenytoin.

  Ikeda T, Higashi A, Matsuda I, Miyoshino S. Ikeda T, et al. Eur J Pediatr. 1979 Sep;132(1):67-8. doi: 10.1007/BF00443207. Eur J Pediatr. 1979. PMID: 499256 No abstract available.
• Transient antibody deficiency and abnormal T suppressor cells induced by phenytoin.

  Dosch HM, Jason J, Gelfand EW. Dosch HM, et al. N Engl J Med. 1982 Feb 18;306(7):406-9. doi: 10.1056/NEJM198202183060707. N Engl J Med. 1982. PMID: 6460185 No abstract available.
• Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.

  Wijetilleka S, Mukhtyar C, Jayne D, Ala A, Bright P, Chinoy H, Harper L, Kazmi M, Kiani-Alikhan S, Li C, Misbah S, Oni L, Price-Kuehne F, Salama A, Workman S, Wrench D, Karim MY. Wijetilleka S, et al. Autoimmun Rev. 2019 May;18(5):535-541. doi: 10.1016/j.autrev.2019.03.010. Epub 2019 Mar 4. Autoimmun Rev. 2019. PMID: 30844552
• The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency.

  Ochs HD, Hollenbaugh D, Aruffo A. Ochs HD, et al. Res Immunol. 1994 Mar-Apr;145(3):210-5; discussion 244-9. Res Immunol. 1994. PMID: 7527577 Review. No abstract available.